Acute and tardive drug-induced akathisia

Drug-Induced Movement Disorders

Volumn , Issue , 2004, Pages 129-164

  Sachdev, Perminder S ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056920348     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (136)

1. Haskovec L. Akathisie. Arch Bohemes Med Clin 1902; 17:704–708.
2. Willis T. The London Practice of Physick. Vol. 1685. London: Thomas Bassett and William Crooke:404.
3. Sigwald J, Grossiord A, Duriel P, et al. Le traitement de la maladie de Parkinson et des manifestations extrapyramidalles par le diethylaminoethyl n-thiophyenylamine (2987 RP): resultants d’une anee d’application. Rev Neurol 1947; 79:683–687.
4. Bing R. Uber einige bemerkenswerte Beglieterscheinungen der “extrapyramidalen Rigidat’ (On some outstanding side effects pf extrapyramidal rigidity) (Akathisie-Mikrographie-Kinesia Paradoxa). Schweiz Med Wochenschr 1923; 4:167–171.
5. Sicard JA. Akathisie and tasikinesie. Presse Med 1923; 31:265–266.
6. Ekbom KA. Asthenia crurum parasthetica (irritable legs). Acta Med Scand 1944; 118:197–198.
7. Van Putten T. The many faces of akathisia. Compr. Psychiatry 1975; 16:43–47.
8. Braude WM, Barnes TR. Late-onset akathisia—An indicant of covert dyskinesia: Two case reports. Am J Psychiatry 1983; 140:611–612.
9. Barnes TR, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985; 42:874–878.
10. Stahl SM. Akathisia and tardive dyskinesia. Changing concepts. Arch Gen Psychiatry 1985; 42:915–917.
11. Lang AE. Withdrawal akathisia: Case reports and a proposed classification of chronic akathisia. Move Disord 1994; 9:188–192.
12. Sachdev P. Akathisia and Restless Legs. New York: Cambridge University Press, 1995.
13. Sachdev P. Research diagnostic criteria for drug-induced akathisia: A proposal. Psychopharmacology 1994; 114:181–186.
14. Healy D, Farquhar G. Immediate effects of droperidol. Hum Psychopharmacol 1998; 13:113–120.
15. Braude WM, Barnes TR, Gore SM. Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 1983; 143:139–150.
16. Sachdev P, Kruk J. Clinical characteristics and risk factors for acute neuroleptic-induced akathisia. Arch Gen Psychiatry 1994; 51:963–974.
17. Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175: 1054–1060.
18. Dufresne RL, Wagner RL. Antipsychotic-withdrawal akathisia versus antipsychotic-induced akathisia: Further evidence for the existence of tardive akathisia. J Clin Psychiatry 1988; 49:435–438.
19. Rosebush PI, Kennedy K, Dalton B, Mazurek MF. Protracted akathisia after risperidone withdrawal. Am J Psychiatry 1997; 154:437–438.
20. Munetz MR, Cornes CL. Akathisia, pseudoakathisia and tardive dyskinesia: Clinical examples. Compr Psychiatry 1982; 23:345–352.
21. Burke RE, Kang UJ, Jankovic J, et al. Tardive akathisia: An analysis of clinical features and response to open therapeutic trials. Move Disord 1989; 4:157–175.
22. Jelliffe SC. Psychopathology of Forced Movements and the Oculogyric Crises of Lethargic Encephalitis. Washington, DC: Nervous & Mental Disease Publishing Co., 1932.
23. Lang AE, Johnson K. Akathisia in idiopathic Parkinson’s disease. Neurology 1987; 37:477–481.
24. Comella CL, Goetz CG. Akathisia in Parkinson’s disease. Move Disord 1994; 9: 545–549.
25. Stewart JT. Akathisia following traumatic brain injury: Treatment with bromocriptine. J Neurol Neurosurg Psychiatry 1989; 52:1200–1201.
26. Kulisevsky J, Berthier ML, Avila A. Unilateral parkinsonism and stereotyped movements following a right lenticular infarction. Move Disord 1996; 11:752–754.
27. Carrazana E, Rossitch E, Martinez J. Unilateral “akathisia” in a patient with AIDS and a toxoplasmosis subthalamic abscess. Neurology 1989; 39:449–450.
28. Yamashita H, Horiguchi J, Mizuno S, Kuramoto Y, Yamawaki S, Inami Y. A case of neuroleptic-induced unilateral akathisia with periodic limb movements in the opposite side during sleep. Psychiatry Clin Neurosci 1999; 53:291–293.
29. Rapoport A. Unilateral akathisia [letter]. Neurology 1989; 39:1648.
30. McCreadie RG, Todd N, Livingstone M, et al. A double blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia. Acta Psychiatr Scand 1988; 78:49–56.
31. Van Putten T, May PR, Marder SR. Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 1984; 41:1036–1039.
32. Safferman AZ, Lieberman JA, Pollack S, et al. Clozapine and akathisia. Biol Psychiatry 1992; 31:753–754.
33. Claghorn J, Honigfeld G, Abuzzahab FS, et al. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7:377–384.
34. Sandoz Pharmaceutical Corporation. Hospital Pharmacist’s Guide to the Clozaril Patient Management System. East Rutherford. NJ: Sandoz, 1991.
35. Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998; 59: 69–75.
36. Levin H, Chengappa KNR, Kambhampati RK, et al. Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients. J Clin Psychiatry 1992; 53:248–251.
37. Peacock L, Solgaard L, Lublin H, Gerlach J. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. Psychopharmacology 1996; 124:188–196.
38. Beasley CM, Sanger T, Satterlee W, et al. Olanzapne versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996; 124: 159–167.
39. Tollefson GD, beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective disorders: Results of an international collaborative trial. Am J Psychiatry 1997; 154:457–465.
40. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi centre, double-blind, parallel group study versus haloperidol. Br J Psychiatry 1995; 166:712–726.
41. Chouinard G, Jones B, Remington GJ, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25–30.
42. Meltzer HY. Atypical antipsychotic drugs. In: Bloom E, Kupfer DJ, Eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven, 1996: 1277–1286.
43. Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 1999; 52(4):782–785.
44. Keck P, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial. Psychopharmacology 1998; 140:173–184.
45. Small JG, Hirsh SR, Arvanitis LA, Miller BG, Link CGG, Murphy AL, et al. Quetapine in patients with schizophrenia—A high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 54(6):549–557.
46. Sachdev P. The epidemiology of drug-induced akathisia. I: Acute akathisia. Schizo Bull 1995; 21:431–450.
47. Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med 1989; 149:2486–2492.
48. Lipinski JF, Mallya G, Zimmerman P, et al. Fluoxetine-induced akathisia: Clinical and theoretical implications. J Clin Psychiatry 1989; 50:339–342.
49. Eli Lilly Pty Ltd. Fluoxetine: Product Information. Eli Lilly, 1993.
50. Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: A review of the literature and consolidating hypotheses. J Clin Psychopharmacol 1997; 17:377–389.
51. Baldassano CF, Truman CJ, Nierenberg A, Ghaemi SN, Sachs GS. Akathisia: A review and case report following paroxetine treatment. Compreh Psychiatry 1996; 37:122–124.
52. 51a. Schillevort I, deBoer A, van der Weide J, Steins LS, Roos RA, Jansen PA, Leufkens HG. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: A case-control study. Pharmocogenetics 2002; 12:235–240.
53. Bruun RD. Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette’s disorder. Am J Psychiatry 1988; 145:621–624.
54. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: Implications for treatment. J Psychopharmacol 1998; 12(2):192–214.
55. Van Putten T, Crumpton E, Yale C. Drug refusal in schizophrenia and the wish to be crazy. Arch Gen Psychiatry 1976; 33:1443–1446.
56. Keckich WA. Neuroleptics. Violence as a manifestation of akathisia. JAMA 1978; 240:2185.
57. Shear MK, Frances A, Weiden P. Suicide associated with akathisia and depot fluphenazine treatment. J Clin Psychopharmacol 1983; 3:235–236.
58. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147:207–210.
59. Wirshing WC, Van Putten T, Rosenberg J, et al. Fluoxetine, akathisia, and suici- dality: Is there a causal connection. Arch Gen Psychiatry 1992; 49:580–581.
60. Cain JW. Poor reponse to fluoxetine: Underlying depression, serotonergic overstimulation, or a ‘therapeutic window’. J Clin Psychiatry 1992; 53:272–277.
61. Fleischhacker WW, Miller CH, Barnes C, et al. The effect of activation procedures on neuroleptic-induced akathisia. Br J Psychiatry 1993; 163:781–784.
62. Walters AS, Hening W, Rubinstein M, et al. A clinical and polysomnographic comparison of neuroleptic-induced akathisia and the idiopathic restless legs syndrome. Sleep 1991; 14:339–345.
63. Zitrin CM, Klein DF, Woerner MG. Behavior therapy, supportive psychotherapy, imipramine and phobias. Arch Gen Psychiatry 1978; 35:307–316.
64. Ekbom KA. Restless legs syndrome. Neurology 1960; 10:868–873.
65. Morgan LK. Restless limbs: A commonly overlooked symptom controlled by “Valium.” Med J Austral 1967:589–594.
66. Coccagna G. Restless legs syndrome. Periodic leg movements in sleep. In: Thorpy MJ, Ed. Handbook of Sleep Disorders. New York: Marcel Dekker, 1990:457–478.
67. Nordstrom AL, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology 1992; 106:433–438.
68. Farde L, Nordstrom A, Weisel F, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992; 49:539–544.
69. Salamone JD. Complex motor and sensorimotor functions of striatal and accumbens dopamine: Involvements in instrumental behavior processes. Psychopharmacology 1992; 107:160–174.
70. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 1980; 10:55–72.
71. Tassin JP, Stinus L, Simon M, et al. Relationship between the locomotor hyperactivity induced by A10 lesions and the destruction of the fronto-cortical dopaminergic innervation in the rat. Brain Res 1978; 141:267–281.
72. Ohashi K, Hamamura T, Lee Y, Fujiwara Y, Kuroda S. Propranolol attenuates haloperidol-induced Fos expression in discrete regions of rat brain: Possible brain regions responsible for akathisia. Brain Res 1998; 802:134–140.
73. Di Mascio M, Di Giovanni G, Di Matteo V, Prisco S, Esposito E. Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergicneurons in the ventral tegmental area. Brain Res Bull 1998; 46:547–554.
74. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45:79–91.
75. Adler LA, Reiter S, Corwin J, et al. Neuroleptic-induced akathisia: Propranolol versus benztropine. Biol Psychiatry 1988; 23:211–213.
76. Adler LA, Peselow E, Rosenthal M, et al. A controlled comparison of the effects of propranolol, benztropine, and placebo on akathisia: an interim analysis. Psychopharmacol Bull 1993; 29:283–286.
77. Tune L, Coyle JT. Acute extrapyramidal side effects: Serum levels of neuroleptics and anticholinergics. Psychopharmacology 1981; 75:9–15.
78. Kruse W. Treatment of drug-induced extrapyramidal symptoms. Dis Nerv Syst 1960; 21:79–81.
79. Sachdev P, Loneragan C. Intravenous challenges of benztropine and propranolol in acute neuroleptic-induced akathisia. Clin Neuropharmacol 1993; 16:324–331.
80. Lipinski JF, Zubenko GS, Barreira P, et al. Propranolol in the treatment of neuroleptic-induced akathisia. Lancet 1983; 2:685–686.
81. Wilbur R, Kulik AV. Propranolol for akathisia. Lancet 1983; 2:917.
82. Adler LA, Angrist B, Reiter S, et al. Neuroleptic-induced akathisia: A review. Psychopharmacology 1989; 97:1–11.
83. Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 1990; 10:12–21.
84. Adler L, Angrist B, Peselow E, et al. A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry 1986; 149:42–45.
85. Kramer MS, Gorkin R, DiJohnson C. Treatment of neuroleptic-induced akathisia with propranolol: A controlled replication study. Hillside J Clin Psychiatry 1989; 11:107–119.
86. Kramer MS, Gorkin RA, DiJohnson C, et al. Propranolol in the treatment of neuroleptic-induced akathisia (NIA) in schizophrenics: A double-blind, placebo-controlled study. Biol Psychiatry 1988; 24:823–827.
87. Irwin M, Sullivan G, Van Putten T. Propranolol as aprimary treatment of neuroleptic-induced akathisia. Hillside J Clin Psychiatry 1988; 10:244–250.
88. Dupuis B, Catteau J, Dumon JP, et al. Comparison of propranolol, sotalol, and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1987; 144:802–805.
89. Nace GS, Wood AJ. Pharmacokinetics of long acting propranolol: Implications for therapeutic use. Clin Pharmacokinet 1987; 13:51–64.
90. Hermesh H, Molcho A, Munitz H. Successful propranolol therapy for neuroleptic-induced akathisia resistant to anticholinergic and benzodiazepine drugs. Clin Neuropharmacol 1988; 11:369–372.
91. Zubenko GS, Cohen BM, Lipinski JF, et al. Use of clonidine in treating neuroleptic-induced akathisia. Psychiatry Res 1984; 13:253–259.
92. Adler LA, Angrist B, Peselow E, et al. Clonidine in neuroleptic-induced akathisia. Am J Psychiatry 1987; 144:235–236.
93. Miller CH, Fleischhacker WW, Ehrmann H, et al. Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacol Bull 1990; 26: 373–376.
94. Miller CH, Hummer M, Pycha R, et al. The effect of ritanserin on treatment-resistant neuroleptic induced akathisia: Case reports. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16:247–251.
95. Weiss D, Aizenberg D, Hermesh H, Zemishlany Z, Munitz H, Radwan M, Weizman A. Cyproheptadine treatment in neuroleptic-induced akathisia. Br J Psychiatry 1995; 167:483–486.
96. 94a. Fischel T, Hermesh H, Aizenberg D, Zemishlany Z, Munitz H, Benjamini Y, Weizman A. Cyproheptadine versus propranolol for the treatment of acute neuroleptic-induced akathisia: A comparative double-blind study. J Clin Psycholpharmacol 2001; 21:612–615.
97. 2 antagonist mianserin: Double-blind, placebo-controlled study. Br J Psychiatry 1999; 174:238–242.
98. Poyurovsky M, Weizman A. Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: Open-labelled study of buspirone and mianserin. Int Clin Psychopharmacol 1997; 12:263–268.
99. DiMascio A, Bernardo DL, Greenblatt DJ, et al. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 1976; 33:599–602.
100. Gelenberg AJ. Amantadine in the treatment of benztropine refractory extrapyramidal disorders induced by antipsychotic drugs. Curr Ther Res 1978; 22:375–380.
101. Zubenko GS, Barreira P, Lipinski JF. Development of tolerance to the therapeutic effect of amantadine on akathisia. J Clin Psychopharmacol 1984; 4:218–220.
102. Danel T, Servant D, Goudemand M. Amitriptyline in the treatment of neuroleptic-induced akathisia. Biol Psychiatry 1988; 23:186–188.
103. Poyurovsky M, Wiezman A. Mirtozapine for neuroleptic-induced akathisia (letter). Am J Psychiatry 2001; 158:819.
104. Friis T, Christensen TR, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo. Acta Psychiatr Scand 1983; 67:178–187.
105. Kabes J, Sikora J, Pisvejc J, et al. Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs. Int Pharmacopsychiatry 1982; 17:185–192.
106. Anfang MK, Pope HG. Treatment of neuroleptic-induced akathisia with nicotine patches. Psychopharmacology 1997; 134:153–156.
107. Olivera AA. Sertraline and akathisia: Spontaneous resolution. Biol Psychiatry 1997; 41:241–242.
108. Inada T, Yagi G, Kaijima K, et al. Clinical variants of tardive dyskinesia in Japan. Jpn J Psychiatry Neurol 1991; 45:67–71.
109. Gibb WR, Lees AJ. The clinical phenomenon of akathisia. J Neurol Neurosurg Psychiatry 1986; 49:861–866.
110. Muscettola G, Barbato G, pampallona S, Casiello M, Bollini P. Extrapyramidal syndromes in neuroleptic-treated patients: Prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol 1999; 19:203–208.
111. McCreadie RG, Robertson LJ, Wiles DH. The Nithsdale Schizophrenia Surveys. IX: Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels. Br J Psychiatry 1992; 160:793–799.
112. Shearer RM, Brownes IT, Curran P. Tardive akathisia and agitated depression during metoclopramide therapy. Acta Psychiatr Scand 1984; 70:428–431.
113. Sachdev P, Hume F, Toohey P, Doutney C. Negative symptoms, cognitive, dysfunction, tardive akathisia and tardive dyskinesia. Acta Psychiatr Scand 1996; 93: 451–459.
114. Sachdev P. The epidemiology of drug-induced akathisia. II: Chronic, tardive and withsrawal akathisias and special populations. Schizo Bull 1995; 21:451–461.
115. Sachdev P. Drug-induced movement disorders in institutionalised adults with mental retardation: Clinical characteristics and risk factors. Austral NZJ Psychiatry 1992; 26:242–248.
116. Gualtieri C, Quade D, Hicks R, et al. Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. Am J Psychiatry 1984; 141:20–23.
117. Klawans HL. The pharmacology of tardive dyskinesia. Am J Psychiatry 1973; 130: 82–86.
118. Sachdev P, Loneragan C. Low-dose apomorphine challenge in tardive akathisia. Neurology 1993; 43:544–547.
119. Cooper JR, Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology. New York: Oxford University Press.
120. Lai H, Carino MA, Horito A. Effects of ethanol on central dopamine functions. Life Sci 1978; 27:19–28.
121. Dustan R, Jackson DM. The demonstration of a change in adrenergic receptor sensitivity in the central nervous system of mice after withdrawal from long-term treatment with haloperidol. Psychopharmacology 1976; 48:105–114.
122. Bartels J, Gaertner HJ, Golfinopoulos G. Akathisia syndrome: Involvement of noradrenergic mechanisms. J Neural Transm 1981; 52:33–39.
123. Cadet JL, Lohr JB. Possible involvement of free radicals in neuroleptic-induced movement disorders: Evidence from tretment of tardive dyskinesia with vitamin E. Ann NY Acad Sci 1989; 570:178–185.
124. Levin H, Chengappa KN, Kambhampati RK, et al. Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients. J Clin Psychiatry 1992; 53:248–251.
125. Safferman AZ, Lieberman JA, Pollack S, et al. Akathisia and clozapine treatment. J Clin Psychopharmacol 1993; 13:286–287.
126. Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, Weizman A. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997;58:318–322.
127. Weiner WJ, Luby ED. Persistent akathisia following neuroleptic withdrawal. Ann Neurol 1983; 13:466–467.
128. Yassa R, Bloom D. Lorazepam and anticholinergics in tardive akathisia. Biol Psychiatry 1990; 27:463–464.
129. Sachdev P, Chee KY. Pharmacological characterization of tardive akathisia. Biol Psychiatry 1990; 28:809–818.
130. Jeste DV, Wyatt RJ. Understanding and Treating Tardive Dyskinesia. New York: Guilford, 1982.
131. Sachdev P, Loneragan C. Intravenous challenges of benztropine and propranolol in tardive akathisia. Psychopharmacology 1993; 16:324–331.
132. Stein MB, Pohlman ER. Tardive akathisia associated with low-dose haloperidol use. J Clin Psychopharmacol 1987; 7:202–203.
133. Yassa R, Iskandar H, Nastase C. Propranolol in the treatment of tardive akathisia: A report of two cases. J Clin Psychopharmacol 1988; 8:283–285.
134. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997; 48:358–362.
135. Kuniyoshi M, Arikawa K, Miura C, et al. Effect of clonazepam on tardive akathisia. Hum Psychopharmacol 1991; 6:39–42.
136. Walters A, Hening W, Chokroverty S, et al. Opioid responsiveness in patients with neuroleptic-induced akathisia. Move Disord 1986; 1:119–127.